272 related articles for article (PubMed ID: 845807)
21. Investigation of the enterohepatic recirculation of Adriamycin and its metabolites by a linked-rat model.
Behnia K; Boroujerdi M
Cancer Chemother Pharmacol; 1998; 41(5):370-6. PubMed ID: 9523732
[TBL] [Abstract][Full Text] [Related]
22. Metabolic disposition and pharmacokinetics of the aldose reductase inhibitor tolrestat in rats, dogs, and monkeys.
Cayen MN; Hicks DR; Ferdinandi ES; Kraml M; Greselin E; Dvornik D
Drug Metab Dispos; 1985; 13(4):412-9. PubMed ID: 2863103
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of [14C]bretylium tosylate in rats.
Kamath BL; Stampfli HF; Lai CM; Yacobi A
J Pharm Sci; 1981 Jun; 70(6):667-9. PubMed ID: 7252812
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
25. Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man.
Hunt CA; Jones RT; Herning RI; Bachman J
J Pharmacokinet Biopharm; 1981 Jun; 9(3):245-60. PubMed ID: 6270295
[TBL] [Abstract][Full Text] [Related]
26. Excretion and metabolism of intramuscularly administered [14C]-haloperidol decanoate in rats.
Matsunaga Y; Nambu K; Oh-e Y; Miyazaki H; Hashimoto M
Arzneimittelforschung; 1986 Mar; 36(3):453-6. PubMed ID: 3707664
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and tissue distribution of ketanserin in rat, rabbit and dog.
Michiels M; Monbaliu J; Meuldermans W; Hendriks R; Geerts R; Woestenborghs R; Heykants J
Arzneimittelforschung; 1988 Jun; 38(6):775-84. PubMed ID: 3178917
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.
Cundy KC; Sueoka C; Lynch GR; Griffin L; Lee WA; Shaw JP
Antimicrob Agents Chemother; 1998 Mar; 42(3):687-90. PubMed ID: 9517952
[TBL] [Abstract][Full Text] [Related]
29. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.
Prueksaritanont T; Gorham LM; Naue JA; Hamill TG; Askew BC; Vyas KP
Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954
[TBL] [Abstract][Full Text] [Related]
30. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
[TBL] [Abstract][Full Text] [Related]
31. Disposition and metabolism of finasteride in dogs.
Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ
Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636
[TBL] [Abstract][Full Text] [Related]
32. Disposition and metabolism of [14C]-haloperidol in rats.
Miyazaki H; Matsunaga Y; Nambu K; Oh-e Y; Yoshida K; Hashimoto M
Arzneimittelforschung; 1986 Mar; 36(3):443-52. PubMed ID: 3707663
[TBL] [Abstract][Full Text] [Related]
33. Metabolism of carprofen, a nonsteroid anti-inflammatory agent, in rats, dogs, and humans.
Rubio F; Seawall S; Pocelinko R; DeBarbieri B; Benz W; Berger L; Morgan L; Pao J; Williams TH; Koechlin B
J Pharm Sci; 1980 Nov; 69(11):1245-53. PubMed ID: 7452450
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose.
Garrett ER; el-Koussi A el-D
J Pharm Sci; 1985 Jan; 74(1):50-6. PubMed ID: 3981418
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the pharmacokinetics of diazepam after single and subchronic doses.
Klotz U; Antonin KH; Bieck PR
Eur J Clin Pharmacol; 1976 Jun; 10(2):121-6. PubMed ID: 964288
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure.
Zamek-Gliszczynski MJ; Abraham TL; Alberts JJ; Kulanthaivel P; Jackson KA; Chow KH; McCann DJ; Hu H; Anderson S; Furr NA; Barbuch RJ; Cassidy KC
Drug Metab Dispos; 2013 Apr; 41(4):714-26. PubMed ID: 23305709
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
[TBL] [Abstract][Full Text] [Related]
38. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP
Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
[TBL] [Abstract][Full Text] [Related]
39. Disposition and cardioselectivity of MDL 74,405, a vitamin E-like free radical scavenger, in rats and dogs after intravenous infusion.
Kuo BS; Mathews BS; Stuhler JD; Carrel BK; Ho J; Rose JQ
Drug Metab Dispos; 1995 Jul; 23(7):757-64. PubMed ID: 7587965
[TBL] [Abstract][Full Text] [Related]
40. The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog.
Christ DD; Wong PC; Wong YN; Hart SD; Quon CY; Lam GN
J Pharmacol Exp Ther; 1994 Mar; 268(3):1199-205. PubMed ID: 8138932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
